Search
Now showing items 1-3 of 3
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
(2016-04)
The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma, but resistance occurs after a median of 6 months. The anti-CTLA4-antibody, ipilimumab, is a standard first-line and ...
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
(2016-09)
Background The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advanced melanoma, as previously ...
The combination of vemurafenib and cobimetinib in advanced melanoma
(TAYLOR & FRANCIS LTD, 2016-11-01)